期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Regulation Mechanism of HBV cccDNA
1
作者 Jun Cheng Min Quan +2 位作者 Min Li Shun-ai Liu Qi Wang 《国际感染病学(电子版)》 CAS 2012年第2期65-73,共9页
Covalently closed circular(ccc)DNA of hepatitis B virus(HBV)existed in the nuclei of HBV infected hepatocytes with a half-life time of 14.3 years in a mathmatic model.Viral protein feedback regulation in HBV life cycl... Covalently closed circular(ccc)DNA of hepatitis B virus(HBV)existed in the nuclei of HBV infected hepatocytes with a half-life time of 14.3 years in a mathmatic model.Viral protein feedback regulation in HBV life cycle to maintain vital viral replication is an important mechanism.Interleukin-6,epithelial growth factor,heme oxygenase-1,histones,and hepatocyte nuclear factors are demonstrated as the key regulators for HBV life cycle.CpG island structure and methylation status are involved in the regulation of HBV DNA replication.Nucleos(t)ide analogues are widely used in the clinical practice for the treatment of chronic hepatitis B patients,although no evidence indicating a direct inhibiton of HBV cccDNA.In the future,along with the study of HBV life cycle,new drugs including RNA interference technique,will pave the way to eliminate the HBV cccDNA from infected hepatocytes resulting final cure of chronic hepatitis B. 展开更多
关键词 Hepatitis B virus(HBV) covalently closed circular(ccc) dna HBV life cycle CpG island structure RNA interference technique
下载PDF
阿德福韦酯对慢性乙型肝炎患者血清ccc DNA的影响 被引量:3
2
作者 王岐洁 陈青锋 +4 位作者 肖萍 杨彦麟 魏喜生 何强 周萍 《中华实验和临床感染病杂志(电子版)》 CAS 2009年第3期41-44,共4页
目的探讨阿德福韦酯对慢性乙型肝炎患者血清HBV ccc DNA的影响。方法40例慢性乙型肝炎患者,按1:1随机分配接受阿德福韦酯或安慰剂治疗,所有患者均治疗52周并在停药后随访52周;应用实时荧光定量聚合酶链反应技术检测慢性乙型肝炎患者0周... 目的探讨阿德福韦酯对慢性乙型肝炎患者血清HBV ccc DNA的影响。方法40例慢性乙型肝炎患者,按1:1随机分配接受阿德福韦酯或安慰剂治疗,所有患者均治疗52周并在停药后随访52周;应用实时荧光定量聚合酶链反应技术检测慢性乙型肝炎患者0周、26周、52周、78周、104周血清HBV ccc DNA及HBV DNA含量。结果治疗组20例患者治疗前(0周)血清HBV ccc DNA中位数水平为8.29×106拷贝/ml(与对照组相比P>0.05);接受阿德福韦酯治疗半年(26周)及1年(52周)血清HBV ccc DNA中位数水平分别为2.61×104拷贝/ml、7.78×103拷贝/ml(与治疗前相比两者P<0.05),停药半年(78周)及1年(104周)血清HBV ccc DNA中位数水平分别为3.38×104拷贝/ml、3.60×104拷贝/ml(与治疗前相比两者P<0.05);接受阿德福韦酯治疗半年及1年血清HBV ccc DNA分别下降2.502log10、3.028log10(与对照组相比两者P<0.05),停药半年及1年血清HBV ccc DNA较停药时上升0.638log10、0.665log10(与对照组相比两者P<0.05)。结论阿德福韦酯对血清HBV ccc DNA有明显抑制作用;血清HBV ccc DNA可作为阿德福韦酯抗病毒治疗的重要监测指标。 展开更多
关键词 慢性乙型肝炎 实时荧光定量聚合酶链反应 共价闭合环状dna
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部